文献速递妇科

早期子宫内膜样子宫内膜癌前哨淋巴结孤立肿瘤细胞的治疗抉择

Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
PubMed 文献 · Gynecol Oncol · 2021-03-05

多机构回顾性研究纳入175例前哨淋巴结孤立肿瘤细胞(<200个细胞且<0.2 mm)、其余为I/II期子宫内膜样子宫内膜癌患者,中位随访31个月。9例(5.1%)复发,化疗与否的宫外复发率相似(5.2% vs 3.8%,p=0.68);控制分期、LVSI和分级后,化疗与EBRT均与无复发生存无关。

要点

  • I/II期子宫内膜样子宫内膜癌伴SLN孤立肿瘤细胞者,腹膜后和/或远处复发风险低(4.6%)。
  • 化疗组宫外复发率与未化疗组相似(5.2% vs 3.8%,p=0.68)。
  • 控制分期、LVSI、分级后,辅助治疗与RFS无显著关联,但证据尚不充分。

核心结论

  • I/II期子宫内膜样子宫内膜癌伴SLN孤立肿瘤细胞者,无论治疗如何,腹膜后和/或远处复发风险低(4.6%)。
  • 初步数据显示辅助治疗可能与无复发生存无显著关联,但需更长随访和更大样本才能给出明确推荐。

研究设计与样本

  • 多机构回顾性研究,纳入175例SLN孤立肿瘤细胞(<200个细胞且<0.2 mm)、其余为I/II期子宫内膜样子宫内膜癌且无微转移或宏转移证据的患者。
  • 采用单因素和多因素Cox比例风险模型评估治疗、肿瘤特征与RFS的关联。

主要发现

  • 中位随访31个月,39%为IB期、12%为II期。
  • 76例(43%)未接受辅助治疗或仅阴道近距离放疗,21例(12%)接受体外 beam 放疗(EBRT),78例(45%)接受化疗±放疗。
  • 9例(5.1%)复发:5例远处、3例腹膜后、1例阴道。
  • 化疗与否的宫外复发率相似(5.2% vs 3.8%,p=0.68)。
  • 控制分期、LVSI和分级后,化疗与RFS无关(HR=0.63,95%CI 0.11-3.52),EBRT与RFS无关(HR=0.90,95%CI 0.22-3.61)。

临床怎么用

  • 对I/II期子宫内膜样子宫内膜癌伴SLN孤立肿瘤细胞者,可考虑弱化辅助治疗,但需个体化评估并告知证据局限性。
  • 化疗更多用于深肌层浸润、LVSI和高级别肿瘤患者,提示治疗选择受肿瘤特征影响。

局限性

  • 回顾性设计,样本量175例,中位随访仅31个月,需更长随访和更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess associations between treatment and recurrence-free survival (RFS) among patients with isolated tumor cells (ITCs) in sentinel lymph nodes (SLN) and otherwise stage I/II endometrioid endometrial cancer (EC). METHODS: A multi-institutional retrospective study of patients with SLN ITCs (<200 cells and < 0.2 mm) was performed. Only patients with otherwise stage I/II EC, endometrioid histology, and no evidence of micro-or macrometastases were included. Univariate and multivariable Cox proportional hazard models were used to evaluate associations between treatment, tumor characteristics, and RFS. RESULTS: 175 patients were included. Median follow up time was 31 months. 39% stage IB and 12% stage II disease. 76 (43%) received no adjuvant therapy or vaginal brachytherapy only (NAT/VBT), 21 (12%) had external beam radiation (EBRT), and 78 (45%) received chemotherapy +/- radiation. Patients who received chemotherapy more often had tumors with deep myoinvasion, lymphovascular space invasion (LVSI), and higher grade. Nine (5.1%) patients recurred; 5 distant, 3 retroperitoneal, and 1 vaginal. Extra-vaginal recurrences were similar in patients with or without chemotherapy (5.2% vs 3.8%, p = 0.68). After controlling for stage, LVSI and grade, chemotherapy and EBRT were not associated with RFS (HR = 0.63, 95%CI 0.11-3.52, and HR = 0.90, 95%CI 0.22-3.61, respectively). Type of lymph node dissection and ITC detection method were not associated with RFS. CONCLUSIONS: Risk of retroperitoneal and/or distant recurrence is low (4.6%) for patients with stage I/II endometrioid EC and ITCs in SLNs regardless of treatment. Our preliminary data suggests that adjuvant therapy may not be significantly associated with RFS. However, longer follow-up time and a larger sample size are needed before definitive recommendations regarding adjuvant therapy for patients with EC and only ITCs in SLN can be made.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Backes FJ, Felix AS, Plante M, et al. Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat? Gynecol Oncol. 2021. PMID: 33678480. doi:10.1016/j.ygyno.2021.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。